LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Meyler's Side Effects of Drugs
Fourteenth Edition
- 14th Edition, Volume 14 - December 7, 2000
- Authors: J. Chalker, M. Leuwer, P.K.M. Lunde, G. McInnes, A. Schaffner, D. Thelle, G.P. Velo, B. Vrhovac
- Editors: Jeffrey K. Aronson, M.N.G. Dukes
- Language: English
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 5 7 4 2 6 - 4
This renowned encyclopaedia of adverse drug reactions, now in its 14th Edition, gives an up-to-date and critical review of the world literature over the past four years.An… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis renowned encyclopaedia of adverse drug reactions, now in its 14th Edition, gives an up-to-date and critical review of the world literature over the past four years.
An international team of well over 100 specialists, have contributed to this fourteenth edition by critically reviewing from the yearly Annuals all that is truly new and informative (and pointing to much which is misleading) in the area of Adverse Drug Reactions. Under the able supervision of two series editors, co-editors and authors have managed to summarise the vast amount of data in a structured and readable form. The high-quality indexes of drugs and of side-effects make this title even more valuable.
The fourteenth edition of Meyler, published in December 2000, provides the world with a fully updated and reliable guide to developments in current knowledge.
Meyler's Side Effects of Drugs, Fourteenth Edition, summarises four Annuals of the series /locate/series/seda"Side Effects of Drugs Annuals". Each Annual can be used independently or as a supplement to this standard encyclopaedic work. Meyler 14 summarises the following Annuals:
/locate/isbn/0-444-82532-0Side Effects of Drugs Annual 20 (published 1997)
/locate/isbn/0-444-82818-4Side Effects of Drugs Annual 21 (published 1998)
/locate/isbn/0-444-50092-8Side Effects of Drugs Annual 22 (published 1999)
/locate/isbn/0-444-50212-2Side Effects of Drugs Annual 23 (published 2000)
1. Central nervous system stimulants and drugs that alter appetite (E.H. Ellinwood, T.H. Lee). 2. Antidepressant drugs (S. Borg, I. Öhman). 3. Lithium (J.W. Jefferson). 4. Drugs of abuse (P.J. Geerlings). 5. Hypnosedatives and anxiolytics (D.B. Menkes). 6. Neuroleptic and antipsychotic drugs (G.M. Simpson, E.H. Pi, and J.J. Sramek). 7. Anticonvulsants (D. Battino, G. Dukes and E. Perucca). 8. Opioid analgesics and antagonists (H. Olsen). 9.1 Antipyretic analgesics (H.M.P. Freie). 9.2. Anti-inflammatory analgesics and drugs used in gout (L. Biscarini). 9.3 Drugs used in gout (L. Biscarin). 10. General anesthetics and anesthetic gases (Z. Baudoin ). 11. Local anesthetics (S. Schug, H.M.D. Cardwell). 12. Neuromuscular blocking agents and skeletal muscle relaxants (M. Leuwer). 13. Drugs affecting autonomic functions or the extrapyramidal system (J.F. Martí Massó). 14. Dermatological drugs, topical agents, and cosmetics (A.C. De Groot). 15. Anti-histamines (H1-receptor antagonists) (M. Andersen). 16. Drugs acting on the respiratory tract (J. Paterson). 17. Positive inotropic drugs etc. (G.D. Johnston). 18. Antianginal and Beta-adrenoceptor antagonists (T.M. MacDonald, P. Lim). 19. Drugs acting on the cerebral and peripheral circulations, including drugs used in migraine (R. Verhaeghe). 20. Antihypertensive drugs (F. Zannad). 21. Diuretics (G.T. MacInnes). 22. Metals (N. Choulis). 23. Metal antagonists (R.H.B. Meyboom, C.C.E. Brodie-Meijer). 24. Antiseptic drugs and disinfectants (F. Hackenberger). 25.1 Beta-lactam antibiotics: Immunological reactions and microbiological resistance (P. Cottagnoud, A. Cerny, K.A. Neftel).
25.2 Reactions typically shared by more than one class of beta-lactam antibiotics (K.A. Neftel, M. Zoppi, A. Cerny, and C. Fux).
25.3 Beta-lactams: Penicillins (A. Cerny, K.A. Neftel, C. Fux, R. Hoigné).
25.4 Beta-lactams: Cephalosporins (C. Fux, K.A. Neftel, A. Cerny, P. Cottagnoud).
25.5 Beta-lactams: Carbapenems, monobactams, and beta-lactamase inhibitors (C. Fux, K.A. Neftel, A. Cerny, P.Cottagnoud).
26.1 Miscellaneous antibacterial drugs: Aminoglycosides, Chloramphenicol and thiamphenicol, Fluoroquinolones, Glycopeptides
(C. Ruef, J. Blaser).
26.2 Miscellaneous antibacterial drugs: Lincomycins, Macrolides, Nitrofurantoin, Polymixins (M. Krause, C. Ruef).
26.3 Miscellaneous antibacterial drugs: Sulfonamides and trimethoprim, Tetracyclines, Other antimicrobial drugs (M. Krause).
27. Antifungal drugs (A. Schaffner). 28. Antiprotozoal drugs (M. Schneemann). 29. Antiviral drugs (P. Vernazza). 30. Drugs used in tuberculosis and leprosy (P. Leuenberger). 31. Antihelminthic drugs (A.M.M. Kaddu). 32. Vaccines (S. Dittmann). 33. Blood, blood components, plasma and plasma products (C. Koch). 34. Intravenous infusions - solutions and emulsions (P. Folb). 35.1. Drugs affecting blood clotting, fibrinolysis, and hemostasis (M. Andréjak). 35.2. Hemostatic agents (P. Giangrande). 36. Gastrointestinal drugs (G. Mignot). 37. Drugs acting on the immune system (T. Vial). 38. Vitamins (E. Helsing). 39.1. Corticotrophins and corticosteroids (J. Costa). 39.2. Prostaglandins (B. True, L.G. Cleland). 40.1. Hormonal contraceptives (M.N.G. Dukes). 40.2. Sex hormones (M.N.G. Dukes). 41. Thyroid and antithyroid drugs (J. Weeke). 42. Insulin, Glucagon, and hypoglycemic drugs (H.M.J. Krans). 43. Miscellaneous hormones (P. Coates). 44. Drugs affecting lipid metabolism (I. Aursnes). 45. Cytostatic and immunosuppressive drugs (P. Folb). 46.1. Radiological contrast media (S. Morcos). 46.2. Radiopharmaceuticals (H. Bagheri, J.A.M. Tafani). 47. Drugs used in ocular treatment (B.C.P. Polak). 48. Risks associated with complementary therapies (E. Ernst). 49. Miscellaneous drugs and materials (H. Haak).
25.2 Reactions typically shared by more than one class of beta-lactam antibiotics (K.A. Neftel, M. Zoppi, A. Cerny, and C. Fux).
25.3 Beta-lactams: Penicillins (A. Cerny, K.A. Neftel, C. Fux, R. Hoigné).
25.4 Beta-lactams: Cephalosporins (C. Fux, K.A. Neftel, A. Cerny, P. Cottagnoud).
25.5 Beta-lactams: Carbapenems, monobactams, and beta-lactamase inhibitors (C. Fux, K.A. Neftel, A. Cerny, P.Cottagnoud).
26.1 Miscellaneous antibacterial drugs: Aminoglycosides, Chloramphenicol and thiamphenicol, Fluoroquinolones, Glycopeptides
(C. Ruef, J. Blaser).
26.2 Miscellaneous antibacterial drugs: Lincomycins, Macrolides, Nitrofurantoin, Polymixins (M. Krause, C. Ruef).
26.3 Miscellaneous antibacterial drugs: Sulfonamides and trimethoprim, Tetracyclines, Other antimicrobial drugs (M. Krause).
27. Antifungal drugs (A. Schaffner). 28. Antiprotozoal drugs (M. Schneemann). 29. Antiviral drugs (P. Vernazza). 30. Drugs used in tuberculosis and leprosy (P. Leuenberger). 31. Antihelminthic drugs (A.M.M. Kaddu). 32. Vaccines (S. Dittmann). 33. Blood, blood components, plasma and plasma products (C. Koch). 34. Intravenous infusions - solutions and emulsions (P. Folb). 35.1. Drugs affecting blood clotting, fibrinolysis, and hemostasis (M. Andréjak). 35.2. Hemostatic agents (P. Giangrande). 36. Gastrointestinal drugs (G. Mignot). 37. Drugs acting on the immune system (T. Vial). 38. Vitamins (E. Helsing). 39.1. Corticotrophins and corticosteroids (J. Costa). 39.2. Prostaglandins (B. True, L.G. Cleland). 40.1. Hormonal contraceptives (M.N.G. Dukes). 40.2. Sex hormones (M.N.G. Dukes). 41. Thyroid and antithyroid drugs (J. Weeke). 42. Insulin, Glucagon, and hypoglycemic drugs (H.M.J. Krans). 43. Miscellaneous hormones (P. Coates). 44. Drugs affecting lipid metabolism (I. Aursnes). 45. Cytostatic and immunosuppressive drugs (P. Folb). 46.1. Radiological contrast media (S. Morcos). 46.2. Radiopharmaceuticals (H. Bagheri, J.A.M. Tafani). 47. Drugs used in ocular treatment (B.C.P. Polak). 48. Risks associated with complementary therapies (E. Ernst). 49. Miscellaneous drugs and materials (H. Haak).
- No. of pages: 1912
- Language: English
- Edition: 14
- Volume: 14
- Published: December 7, 2000
- Imprint: Elsevier Science
- eBook ISBN: 9780080574264
JA
Jeffrey K. Aronson
Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.
Affiliations and expertise
consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals TrustMD
M.N.G. Dukes
Affiliations and expertise
Oslo, NorwayJC
J. Chalker
Affiliations and expertise
Yelmpton, UKML
M. Leuwer
Affiliations and expertise
Liverpool, UKPL
P.K.M. Lunde
Affiliations and expertise
Oslo, NorwayGM
G. McInnes
Affiliations and expertise
Glasgow, ScotlandAS
A. Schaffner
Affiliations and expertise
Zürich, SwitzerlandDT
D. Thelle
Affiliations and expertise
Göteborg, SwedenGV
G.P. Velo
Affiliations and expertise
Verona, ItalyBV
B. Vrhovac
Affiliations and expertise
Zagreb, Croatia